Recently reported Phase 1 data of Restem-L demonstrated a clinically meaningful efficacy and significant reduction in steroid ...

YTS-109 is under clinical development by Bristar Immunotech Biotechnology and currently in Phase I for Polymyositis.

ULSCs is under clinical development by RESTEM and currently in Phase I for Polymyositis. According to GlobalData, Phase I drugs for Polymyositis does not have sufficient historical data to build an ...

Inflammatory Myositis Overview Myositis refers to muscle inflammation and is commonly associated with inflammatory myopathies, including polymyositis, dermatomyositis, cancer-associated myositis ...

Melanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis (DM) is a rare systemic autoimmune disease associated with a high rate of mortality attributable to rapidly progressive ...